Literature DB >> 16716167

Serum substance P and calcitonin gene-related peptide levels in Behçet's disease and their association with disease activity.

T Aki1, Y Karincaoglu, M Seyhan, K Batcioglu.   

Abstract

BACKGROUND: Substance P (SP) and calcitonin gene-related peptide (CGRP) are neuropeptides that have a role in several cutaneous diseases and inflammations. Aim. To evaluate SP, CGRP and serum interleukin (IL)-8 levels in Behçet's disease (BD) and to explore the relationship of these peptides with BD activity.
METHODS: The study group comprised 30 patients with BD, and 30 healthy individuals acted as controls. Serum levels of SP, CGRP and IL-8 were determined by micro-ELISA test during the active and inactive disease periods of patients with BD. These data were compared with each other and controls. Active and inactive periods of BD were established.
RESULTS: The mean +/- SD serum CGRP (ng/ml) and IL-8 levels (pg/ml) in inactive BD (5.87 +/- 2.49 and 0.62 +/- 0.24, respectively) were significantly higher than the control group (4.74 +/- 1.17 and 0.46 +/- 0.11) (P < 0.05 for both). The difference between serum CGRP and IL-8 levels in active BD were also significantly higher than in inactive BD (P < 0.05 for both). Serum SP values (ng/ml) in active BD (18.27 +/- 5.38) were significantly higher than in inactive BD (15.26 +/- 5.74) and controls (12.6 +/- 4.45) (P < 0.05 for all), whereas the difference between the serum SP values in inactive BD and the control group was not statistically significant (P > 0.05).
CONCLUSION: Serum SP and CGRP may have a role in the pathogenesis of BD. In addition, serum IL-8, SP and CGRP levels can be used as laboratory parameters indicating activity in BD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16716167     DOI: 10.1111/j.1365-2230.2006.02157.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  4 in total

1.  Evaluation of the fungiform papillae number in Behçet's disease.

Authors:  Gökçen Akçiçek; Nihal Avcu; Serdar Uysal
Journal:  Clin Oral Investig       Date:  2014-08-06       Impact factor: 3.573

Review 2.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

3.  [Comments on the pathogenesis of Behçet's disease. A key to understanding new therapies?].

Authors:  U Pleyer; D Hazirolan; N Stübiger
Journal:  Ophthalmologe       Date:  2012-06       Impact factor: 1.059

4.  Pathophysiology of the Behçet's Disease.

Authors:  Umit Türsen
Journal:  Patholog Res Int       Date:  2011-10-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.